Results 181 to 190 of about 177,768 (257)

Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand

open access: yesPediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Background The survival outcomes among children with acute myeloid leukemia (AML) in low‐ and middle‐income countries are still poor despite adopting modern treatment regimens from developed countries. The study aimed to identify additional potential determinant factors for relapse and death among children with AML in Thailand. Methods In all,
Piya Rujkijyanont   +20 more
wiley   +1 more source

Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study

open access: yesThe Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic ...
Alex Jenei   +10 more
wiley   +1 more source

Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease

open access: yesACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD). This study evaluates the reliability and construct validity of the PGALD.
Eileen Rife   +70 more
wiley   +1 more source

A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease [PDF]

open access: yes, 2018
Baker, Turner S.   +7 more
core   +1 more source

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset

open access: yesCancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Aim Tumor flare reaction (TFR) is characterized by an increase in tumor size during immunotherapy, often resembling disease progression. This study explores the relationship between anti‐tumor drugs and tumor flare reaction (TFR) through the FAERS database to assist clinicians in better patient management.
Wei Wang   +7 more
wiley   +1 more source

Two Cases of Systemic Lupus Erythematosus With Castleman Disease. [PDF]

open access: yesCureus
Bravo-Andrade AM   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy